Fidelity Investments’s Pasithea Therapeutics KTTA Stock Holding History

Fidelity Investments’s Portfolio KTTA Stock Details KTTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-49	Closed	-$256	–	5632
2024 Q2	$256	Buy	+49	New	+$320	﹤0.01%	4909

Other funds holding KTTA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments's KTTA Position: Q3 2024 in Review

Fidelity Investments sold out of Pasithea Therapeutics (KTTA) in Q3 2024, closing a stake of 49 shares — an estimated $256 sold.

Fidelity Investments first reported a position in KTTA in Q2 2024 and held it in 1 quarter. The position peaked at $256 in Q2 2024. 6 funds tracked by Wall St. Rank hold KTTA as of Q3 2024.

Fidelity Investments reported no remaining Pasithea Therapeutics position as of Q3 2024 after selling out during the quarter.
Fidelity Investments sold 49 Pasithea Therapeutics shares in Q3 2024, an estimated $256.
Fidelity Investments first reported a position in Pasithea Therapeutics in Q2 2024 and held it in 1 quarter.
Fidelity Investments's Pasithea Therapeutics position peaked at $256 in Q2 2024.
6 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q3 2024.

Based on Fidelity Investments's 13F filing for Q3 2024, filed 13 Nov 2024.